Trading of Bon Natural Life was halted at 10:00 AM EST due to "LULD pause". Bon Natural Life (BON) Competitors $1.92 +0.38 (+24.68%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock BON vs. BPTH, HSTO, PTPI, HEPA, ORGS, PBLA, BPTSY, SMFL, TRVN, and VINCShould you be buying Bon Natural Life stock or one of its competitors? The main competitors of Bon Natural Life include Bio-Path (BPTH), Histogen (HSTO), Petros Pharmaceuticals (PTPI), Hepion Pharmaceuticals (HEPA), Orgenesis (ORGS), Panbela Therapeutics (PBLA), Biophytis (BPTSY), Smart for Life (SMFL), Trevena (TRVN), and Vincerx Pharma (VINC). These companies are all part of the "pharmaceutical products" industry. Bon Natural Life vs. Its Competitors Bio-Path Histogen Petros Pharmaceuticals Hepion Pharmaceuticals Orgenesis Panbela Therapeutics Biophytis Smart for Life Trevena Vincerx Pharma Bio-Path (NASDAQ:BPTH) and Bon Natural Life (NASDAQ:BON) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership. Does the media prefer BPTH or BON? In the previous week, Bon Natural Life had 2 more articles in the media than Bio-Path. MarketBeat recorded 2 mentions for Bon Natural Life and 0 mentions for Bio-Path. Bon Natural Life's average media sentiment score of 0.33 beat Bio-Path's score of -1.00 indicating that Bon Natural Life is being referred to more favorably in the news media. Company Overall Sentiment Bio-Path Negative Bon Natural Life Neutral Is BPTH or BON more profitable? Bon Natural Life's return on equity of 0.00% beat Bio-Path's return on equity.Company Net Margins Return on Equity Return on Assets Bio-PathN/A -2,842.40% -337.48% Bon Natural Life N/A N/A N/A Which has higher earnings & valuation, BPTH or BON? Bon Natural Life has higher revenue and earnings than Bio-Path. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBio-PathN/AN/A-$16.08MN/AN/ABon Natural Life$23.84M0.01$400KN/AN/A Which has more volatility & risk, BPTH or BON? Bio-Path has a beta of -0.03, indicating that its stock price is 103% less volatile than the S&P 500. Comparatively, Bon Natural Life has a beta of -0.46, indicating that its stock price is 146% less volatile than the S&P 500. Do insiders & institutionals believe in BPTH or BON? 5.7% of Bio-Path shares are owned by institutional investors. Comparatively, 0.6% of Bon Natural Life shares are owned by institutional investors. 0.7% of Bio-Path shares are owned by insiders. Comparatively, 26.5% of Bon Natural Life shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryBon Natural Life beats Bio-Path on 7 of the 9 factors compared between the two stocks. Get Bon Natural Life News Delivered to You Automatically Sign up to receive the latest news and ratings for BON and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart BON vs. The Competition Export to ExcelMetricBon Natural LifeCONSM PD IndustryDiscretionary SectorNASDAQ ExchangeMarket Cap$260K$2.33B$8.48B$10.01BDividend YieldN/A4.08%3.00%4.53%P/E RatioN/A17.5118.4026.28Price / Sales0.012.825.13121.13Price / Cash0.1516.6317.0859.76Price / Book0.011.735.056.41Net Income$400K$103.49M$255.12M$270.56M7 Day Performance29.73%6.07%1.38%3.01%1 Month Performance46.56%7.00%20.53%9.74%1 Year PerformanceN/A-8.91%55.37%26.68% Bon Natural Life Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BONBon Natural Life1.0127 of 5 stars$1.92+24.7%N/AN/A$260K$23.84M0.00100Short Interest ↓Gap UpTrading HaltedHigh Trading VolumeBPTHBio-Path0.5195 of 5 stars$0.12-6.5%N/A-88.5%$997KN/A0.0010Negative NewsHSTOHistogenN/A$0.00flatN/A-99.9%$918K$19K0.0020Gap UpPTPIPetros Pharmaceuticals0.7333 of 5 stars$0.03flatN/A-99.7%$901K$5.11M-0.0120Gap DownHEPAHepion Pharmaceuticals0.3095 of 5 stars$0.08+17.6%N/A-99.8%$892KN/A-0.0220Negative NewsORGSOrgenesisN/A$0.17-78.1%N/AN/A$816K$662K0.00150Gap DownPBLAPanbela Therapeutics0.0839 of 5 stars$0.15flatN/A-86.1%$728KN/A0.006Gap DownBPTSYBiophytisN/A$2.00flatN/AN/A$702KN/A0.0030SMFLSmart for LifeN/A$0.00-90.4%N/A-99.6%$252K$11.11M0.00110Gap DownTRVNTrevena1.4672 of 5 stars$0.25flat$5.00+1,900.0%N/A$240K$443K-0.0140Gap UpVINCVincerx Pharma2.3503 of 5 stars$0.03+3.5%$40.00+122,976.9%-99.7%$170KN/A0.0060 Related Companies and Tools Related Companies Bio-Path Competitors Histogen Competitors Petros Pharmaceuticals Competitors Hepion Pharmaceuticals Competitors Orgenesis Competitors Panbela Therapeutics Competitors Biophytis Competitors Smart for Life Competitors Trevena Competitors Vincerx Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BON) was last updated on 9/9/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bon Natural Life Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Bon Natural Life With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BON Stock Alerts